Biological
milatuzumab
milatuzumab is a biological therapy with 6 clinical trials. Historical success rate of 80.0%.
Total Trials
6
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
80.0%
Based on 4 completed trials
Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Terminated
1(17%)
Phase Distribution
Ph phase_1
6
100%
Phase Distribution
6
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
6(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(4)
Terminated(1)
Other(1)
Detailed Status
Completed4
unknown1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
80.0%
Most Advanced
Phase 1
Trials by Phase
Phase 16 (100.0%)
Trials by Status
unknown117%
completed467%
terminated117%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_1
Phase Ib Study of SC Milatuzumab in SLE
NCT01845740
terminatedphase_1
Phase I Study of Milatuzumab for Graft Versus Host Disease
NCT01663766
completedphase_1
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
NCT00603668
completedphase_1
Phase I/II Study of hLL1 in Multiple Myeloma
NCT00421525
completedphase_1
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT00989586
Clinical Trials (6)
Showing 6 of 6 trials
NCT01845740Phase 1
Phase Ib Study of SC Milatuzumab in SLE
NCT01663766Phase 1
Phase I Study of Milatuzumab for Graft Versus Host Disease
NCT00603668Phase 1
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
NCT00421525Phase 1
Phase I/II Study of hLL1 in Multiple Myeloma
NCT00989586Phase 1
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT00868478Phase 1
The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
All 6 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 6